TARACTAN
LOE ApproachingNDAORALTABLET
Approved
May 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TARACTAN is an oral small-molecule tablet approved by Roche in 1962 for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly documented in available data, limiting immediate clinical characterization.
LOE Approaching
Product is approaching loss of exclusivity with low linked job volume, suggesting a mature brand with reduced team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for TARACTAN roles, reflecting its LOE-approaching lifecycle stage. Career opportunities on this product are limited; professionals should consider roles on growth-stage assets or franchise transitions.
Brand ManagerProduct Manager
Worked on TARACTAN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.